LEGN — Legend Biotech Corporation

Summary of Legend Biotech Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Q4 2025 revenue reached $306 million, up 64% year-over-year, driven by CARVYKTI sales.
• CARVYKTI Sales: Net trade sales for CARVYKTI were approximately $555 million in Q4, a 66% increase year-over-year.
• Gross Margin: Maintained at 61%, with CARVYKTI gross margin at 57%.
• Operating Margin: Improved significantly from negative 142% in Q2 2023 to negative 6% in Q4 2025.
• Adjusted Net Income: Reported positive adjusted net income of $2.5 million, a turnaround from a $59 million adjusted net loss a year ago.
• Cash Position: Ended the year with $949 million in cash, providing a strong financial foundation for future growth.

2. Strategic Updates and Business Highlights

• CARVYKTI Expansion: The company has achieved profitability for CARVYKTI and aims for company-wide profitability in 2026. The drug is now utilized in 14 global markets, with a manufacturing capacity to support 10,000 doses annually.
• Clinical Data: Presented compelling long-term data at recent medical conferences, reinforcing CARVYKTI's efficacy, particularly in earlier treatment lines for multiple myeloma.
• Manufacturing Success: Achieved a 97% overall manufacturing success rate, with plans for further capacity expansion in partnership with Johnson & Johnson.
• Pipeline Development: Focus on advancing in vivo CAR-T programs and potential IND filings by year-end, alongside exploring synergistic business development opportunities.

3. Forward Guidance and Outlook

• Growth Expectations: The company anticipates continued sequential growth for CARVYKTI throughout 2026, targeting approximately 50% top-line growth from 2025.
• Market Penetration: Less than 5% of patients in earlier lines are currently treated with BCMA-targeting agents, indicating significant growth potential.
• Investment Priorities: Focus on advancing R&D, business development, and supporting CARVYKTI's profit expansion while maintaining disciplined expense management.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: The landscape is becoming increasingly competitive, especially with new entrants and therapies, including bispecifics, which could impact CARVYKTI's market share.
• Market Penetration: Despite growth, CAR-T therapies remain underpenetrated in earlier treatment lines, presenting a challenge to capture the full market potential.
• Regulatory Environment: The FDA's recent standard review classification for a competitor’s application raises concerns about the competitive dynamics and the potential impact on CARVYKTI's market positioning.

5. Notable Q&A Insights

• Community Adoption: The company is actively working on expanding CARVYKTI's presence in community hospitals, which now represent one-third of treatment centers. Education and effective patient management strategies are crucial for this expansion.
• Bridging Therapy: Evidence supporting the use of bridging therapies to improve patient outcomes is gaining traction, with updates to guidelines reinforcing this approach.
• Future Data Releases: Anticipated clinical data from in vivo programs is expected to be presented at major medical meetings in 2026, with ongoing monitoring of patient outcomes to ensure alignment with long-term efficacy expectations.

Overall, Legend Biotech is positioned for growth with a strong financial foundation and strategic focus on expanding CARVYKTI's market presence while navigating competitive and regulatory challenges.